H.C. Wainwright analyst Andrew Fein maintained a Buy rating on AC Immune SA today and set a price target of $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein has given his Buy rating due to a combination of factors that highlight AC Immune SA’s innovative approach in the field of neurodegenerative diseases. The company’s core value lies in its unique vaccine platform, which includes promising candidates like ACI-24.060, ACI-35.030, and ACI-7104, positioning it as a leader in active immunization for Alzheimer’s, tauopathies, and Parkinson’s diseases.
Moreover, the recent publication in Nature Communications about AC Immune’s TDP-43 PET tracer, [18F]ACI-19626, marks a significant breakthrough. This development overcomes previous challenges in TDP-43 tracer development and establishes AC Immune as a pioneer in this area. The tracer not only serves as a diagnostic tool but also as a strategic enabler for therapeutic development, potentially transforming patient selection and trial processes in ALS and FTD. This expansion beyond its vaccine programs enhances AC Immune’s value proposition, supporting the Buy rating.